In the BioHarmony Drug Report Database
Calaspargase pegol-mknl
Asparlas (calaspargase pegol) is an enzyme pharmaceutical. Calaspargase pegol was first approved as Asparlas on 2018-12-20. It is used to treat precursor cell lymphoblastic leukemia-lymphoma in the USA.
Trade Name
|
Asparlas |
|---|---|
Common Name
|
calaspargase pegol |
ChEMBL ID
|
CHEMBL2108728 |
Indication
|
precursor cell lymphoblastic leukemia-lymphoma |
Drug Class
|
Enzymes; PEGylated compounds |
Image (chem structure or protein)
